{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:36:45Z","timestamp":1784547405997,"version":"3.55.0"},"reference-count":72,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2025.12800","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T12:59:18Z","timestamp":1737032358000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon\u2011\u03b1: A case report"],"prefix":"10.3892","volume":"29","author":[{"given":"Meng-Xiao","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261031, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Lin","family":"Di","sequence":"additional","affiliation":[{"name":"Department of Immunology, Shandong Second Medical University, Weifang, Shandong 261053, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261031, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261031, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261031, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"key20250211104527_b1-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"key":"key20250211104527_b2-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: A narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J Blood Med"},{"issue":"100825","key":"key20250211104527_b3-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: Modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"key":"key20250211104527_b4-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"key20250211104527_b5-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1774-9987.2004.00187.x","article-title":"Therapeutic plateletpheresis in a case of symptomatic thrombocytosis in chronic myeloid leukemia","volume":"8","author":"Thakral","year":"2004","journal-title":"Ther Apher Dial"},{"issue":"e476","key":"key20250211104527_b6-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.476","article-title":"Chronic myeloid leukemia: A case of extreme thrombocytosis causing syncope and myocardial infarction","volume":"8","author":"Ebrahem","year":"2016","journal-title":"Cureus"},{"key":"key20250211104527_b7-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/jclinpath-2015-203498","article-title":"Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations","volume":"69","author":"Turakhia","year":"2016","journal-title":"J Clin Pathol"},{"key":"key20250211104527_b8-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/j.clml.2020.11.003","article-title":"Clinical and prognostic features of essential thrombocythemia: Comparison of 2001 WHO Versus 2008\/2016 WHO criteria in a large single-center cohort","volume":"21","author":"Chiatamone Ranieri","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20250211104527_b9-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1517\/14656566.2013.799140","article-title":"The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment","volume":"14","author":"Haznedaroglu","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"bcr2014204564","key":"key20250211104527_b10-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204564","article-title":"Chronic myeloid leukaemia with extreme thrombocytosis","volume":"2015","author":"Verma","year":"2015","journal-title":"BMJ Case Rep"},{"key":"key20250211104527_b11-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/s0037-1963(01)90114-3","article-title":"Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition","volume":"38 (Suppl 8)","author":"Talpaz","year":"2001","journal-title":"Semin Hematol"},{"key":"key20250211104527_b12-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: A retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"key":"key20250211104527_b13-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.2147\/OTT.S142587","article-title":"Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors","volume":"10","author":"Liu","year":"2017","journal-title":"Onco Targets Ther"},{"key":"key20250211104527_b14-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol"},{"key":"key20250211104527_b15-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2019.317","article-title":"Recent insights regarding the molecular basis of myeloproliferative neoplasms","volume":"35","author":"Jang","year":"2020","journal-title":"Korean J Intern Med"},{"key":"key20250211104527_b16-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5045\/br.2014.49.2.127","article-title":"A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow","volume":"49","author":"Byun","year":"2014","journal-title":"Blood Res"},{"key":"key20250211104527_b17-ETM-29-3-12800","first-page":"135","article-title":"Hematologic abnormalities in a patient with chronic myelogenous leukemia with advanced myelofibrosis were improved by G-CSF","volume":"35","author":"Hiruma","year":"1994","journal-title":"Rinsho Ketsueki"},{"key":"key20250211104527_b18-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.2017.75.4663","article-title":"Front-line treatment options for chronic-phase chronic myeloid leukemia","volume":"36","author":"Shah","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20250211104527_b19-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","article-title":"An overview and update of chronic myeloid leukemia for primary care physicians","volume":"36","author":"Granatowicz","year":"2015","journal-title":"Korean J Fam Med"},{"key":"key20250211104527_b20-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/njcp.njcp_1401_21","article-title":"Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: A case report","volume":"25","author":"Rajabto","year":"2022","journal-title":"Niger J Clin Pract"},{"key":"key20250211104527_b21-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11899-020-00588-z","article-title":"Thrombocytosis and thrombosis: Is there really a correlation?","volume":"15","author":"Galvez","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"key20250211104527_b22-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1097\/MPH.0000000000002216","article-title":"Pediatric chronic myeloid leukemia presenting with extreme thrombocytosis and acute upper gastrointestinal hemorrhage: A case report","volume":"43","author":"Zheng","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"e57650","key":"key20250211104527_b23-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057650","article-title":"A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells","volume":"8","author":"Turroni","year":"2013","journal-title":"PLoS One"},{"key":"key20250211104527_b24-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1080\/10428190410001683732","article-title":"Megakaryocyte features and bcr\/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy-a fluorescence in-situ hybridization study","volume":"45","author":"Thiele","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"key20250211104527_b25-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1046\/j.1365-2141.1998.01115.x","article-title":"BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation","volume":"103","author":"ten Bosch","year":"1998","journal-title":"Br J Haematol"},{"issue":"348","key":"key20250211104527_b26-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0348-z","article-title":"Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia","volume":"30","author":"Bennour","year":"2013","journal-title":"Med Oncol"},{"key":"key20250211104527_b27-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2257.2002.00413.x","article-title":"BCR\/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML)","volume":"24","author":"Arana-Trejo","year":"2002","journal-title":"Clin Lab Haematol"},{"key":"key20250211104527_b28-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.4238\/vol7-4gmr485","article-title":"Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr\/Abl fusion transcripts","volume":"7","author":"Polampalli","year":"2008","journal-title":"Genet Mol Res"},{"key":"key20250211104527_b29-ETM-29-3-12800","first-page":"444","article-title":"Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients","volume":"21","author":"Al-Achkar","year":"2016","journal-title":"J BUON"},{"key":"key20250211104527_b30-ETM-29-3-12800","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood.V94.7.2200.419a33_2200_2207","article-title":"BCR\/ABL mRNA and the P210(BCR\/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients","volume":"94","author":"Pane","year":"1999","journal-title":"Blood"},{"issue":"170","key":"key20250211104527_b31-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-0930-x","article-title":"Coexistence of P190 and P210 BCR\/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib","volume":"4","author":"Junmei","year":"2015","journal-title":"Springerplus"},{"key":"key20250211104527_b32-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.3390\/curroncol29110645","article-title":"Long-term molecular remission after treatment with imatinib in a chronic myeloid leukemia patient with extreme thrombocytosis harboring rare e14a3 (b3a3) BCR::ABL1 transcript: A case report","volume":"29","author":"Zhang","year":"2022","journal-title":"Curr Oncol"},{"key":"key20250211104527_b33-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","article-title":"Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway","volume":"13","author":"Puil","year":"1994","journal-title":"EMBO J"},{"key":"key20250211104527_b34-ETM-29-3-12800","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.V93.7.2369","article-title":"Constitutive activation of the JAK2\/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines","volume":"93","author":"Liu","year":"1999","journal-title":"Blood"},{"key":"key20250211104527_b35-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: Analysis of characteristics, outcomes and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"key20250211104527_b36-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0950-3536(97)80003-0","article-title":"BCR-ABL gene variants","volume":"10","author":"Melo","year":"1997","journal-title":"Baillieres Clin Haematol"},{"key":"key20250211104527_b37-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cancergencyto.2007.11.009","article-title":"Philadelphia chromosome-positive chronic myeloid leukemia with p190(BCR-ABL) rearrangement, overexpression of the EVI1 gene and extreme thrombocytosis: A case report","volume":"181","author":"Balatzenko","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"key20250211104527_b38-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41375-020-01082-4","article-title":"Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets","volume":"35","author":"Adnan-Awad","year":"2021","journal-title":"Leukemia"},{"key":"key20250211104527_b39-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1182\/blood.v99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"key":"key20250211104527_b40-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7534\/j.issn.1009-2137.2016.02.012","article-title":"Comparison of clinical outcomes between P190 and P210 trans-cripts in adult Ph chromosome positive acute lymphoblastic leukemia in the new Era of TKI","volume":"24","author":"Qiu","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20250211104527_b41-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.4238\/gmr16029541","article-title":"BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia","volume":"16","author":"Vasconcelos","year":"2017","journal-title":"Genet Mol Res"},{"key":"key20250211104527_b42-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.ircmb.2021.09.003","article-title":"The MPL mutation","volume":"365","author":"Guglielmelli","year":"2021","journal-title":"Int Rev Cell Mol Biol"},{"key":"key20250211104527_b43-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00277-021-04485-0","article-title":"Thrombocytosis in children and adolescents-classification, diagnostic approach and clinical management","volume":"100","author":"Stockklausner","year":"2021","journal-title":"Ann Hematol"},{"key":"key20250211104527_b44-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/bjh.19161","article-title":"Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists","volume":"203","author":"Rottenstreich","year":"2023","journal-title":"Br J Haematol"},{"key":"key20250211104527_b45-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/bjh.19279","article-title":"Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed inidiopathic multicentric Castleman disease","volume":"204","author":"Rubenstein","year":"2024","journal-title":"Br J Haematol"},{"key":"key20250211104527_b46-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11899-021-00655-z","article-title":"The evolving landscape of frontline therapy in chronic phase chronic myeloid leukemia (CML)","volume":"16","author":"Wolfe","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"key20250211104527_b47-ETM-29-3-12800","author":"Flynn"},{"issue":"e27134","key":"key20250211104527_b48-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027134","article-title":"Management of chronic myeloid leukemia presenting with isolated thrombocytosis and complex Philadelphia chromosome: A case report","volume":"100","author":"Gao","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"key20250211104527_b49-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/cbf.3625","article-title":"Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib","volume":"39","author":"Repsold","year":"2021","journal-title":"Cell Biochem Funct"},{"issue":"1076029619858409","key":"key20250211104527_b50-ETM-29-3-12800","doi-asserted-by":"publisher","DOI":"10.1177\/1076029619858409","article-title":"TKI-related platelet dysfunction does not correlate with bleeding in patients with chronic phase-chronic myeloid leukemia with complete hematological response","volume":"25","author":"Sener","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"key20250211104527_b51-ETM-29-3-12800","first-page":"1314","article-title":"Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML","volume":"19","author":"Shu","year":"2011","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20250211104527_b52-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/jemt.24079","article-title":"Ex vivo platelet morphology assessment of chronic myeloid leukemia patients before and after Imatinib treatment","volume":"85","author":"Repsold","year":"2022","journal-title":"Microsc Res Tech"},{"key":"key20250211104527_b53-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/15384047.2017.1294289","article-title":"Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression","volume":"18","author":"Akram","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"key20250211104527_b54-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/sj.thj.6200319","article-title":"High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib","volume":"5","author":"Al-Ali","year":"2004","journal-title":"Hematol J"},{"key":"key20250211104527_b55-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","article-title":"Abl tyrosine kinase inhibitors for overriding Bcr-Abl\/T315I: From the second to third generation","volume":"8","author":"Tanaka","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20250211104527_b56-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: First approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"key20250211104527_b57-ETM-29-3-12800","first-page":"79","article-title":"Cardiovascular toxicity associated with tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"1","author":"Binzaid","year":"2021","journal-title":"Gulf J Oncolog"},{"key":"key20250211104527_b58-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2019.10.036","article-title":"Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors","volume":"301","author":"Caocci","year":"2020","journal-title":"Int J Cardiol"},{"key":"key20250211104527_b59-ETM-29-3-12800","first-page":"S30","article-title":"Use of interferon in the treatment of chronic myeloproliferative disorders","volume":"23 (2 Suppl 1)","author":"Robak","year":"1992","journal-title":"Acta Haematol Pol"},{"key":"key20250211104527_b60-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94 (Suppl 2)","author":"Talpaz","year":"2015","journal-title":"Ann Hematol"},{"key":"key20250211104527_b61-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","article-title":"The role of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"18","author":"Kujawski","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20250211104527_b62-ETM-29-3-12800","first-page":"420","article-title":"Interferon therapy in essential thrombocythemia","volume":"143","author":"Seewann","year":"1993","journal-title":"Wien Med Wochenschr"},{"key":"key20250211104527_b63-ETM-29-3-12800","first-page":"400","article-title":"Thrombocytosis in chronic myelogenous leukemia (CML) controlled by interferon alpha (IFN-alpha)","volume":"30","author":"Koike","year":"1989","journal-title":"Rinsho Ketsueki"},{"key":"key20250211104527_b64-ETM-29-3-12800","first-page":"31","article-title":"Interferon therapy, but not busulfan restores normal-sized megakaryopoiesis in CML-a comparative histo- and immunomorphometric study","volume":"11","author":"Thiele","year":"1996","journal-title":"Anal Cell Pathol"},{"key":"key20250211104527_b65-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00277-021-04606-9","article-title":"Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment","volume":"100","author":"Kong","year":"2021","journal-title":"Ann Hematol"},{"key":"key20250211104527_b66-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"R\u00fcdiger","year":"2007","journal-title":"Lancet"},{"key":"key20250211104527_b67-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1182\/blood-2003-03-0981","article-title":"IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment","volume":"103","author":"Gabriele","year":"2004","journal-title":"Blood"},{"key":"key20250211104527_b68-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"key20250211104527_b69-ETM-29-3-12800","first-page":"331","article-title":"Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors","volume":"15","author":"McGlave","year":"1987","journal-title":"Exp Hematol"},{"key":"key20250211104527_b70-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00205575","article-title":"A phase I trial of recombinant gamma interferon in patients with cancer","volume":"20","author":"Foon","year":"1985","journal-title":"Cancer Immunol Immunother"},{"key":"key20250211104527_b71-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3760\/cma.j.issn.0578-1426.2018.09.006","article-title":"Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"57","author":"Dou","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"key20250211104527_b72-ETM-29-3-12800","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/10428199609054827","article-title":"Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha","volume":"23","author":"O'Brien","year":"1996","journal-title":"Leuk Lymphoma"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:45:42Z","timestamp":1739263542000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2025.12800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2025.12800","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"article-number":"50"}}